InMed Pharmaceuticals Inc. provided a 2026 pharmaceutical development outlook, highlighting progress on INM-901 for Alzheimer's disease and INM-089 for dry age-related macular degeneration. The company plans a pre-IND meeting with the FDA for INM-901 in Q3 2026 and targets IND submission and Phase 1 trial initiation in 2027.
Key takeaways
Pre-IND meeting with FDA for INM-901 in Q3 2026
IND submission and Phase 1 clinical trial initiation for INM-901 targeted for 2027
Pre-IND meeting planned for INM-089 in Q4 2026
INM-901 reduced inflammatory biomarkers IFN-γ, TNF-α, IL-1β, KC-GRO, IL-2, NfL in 5xFAD mouse model
INM-901 demonstrated neuroprotection, neuritogenesis, and positive behavioral trends in preclinical studies